Pawel Buda
R&D Centre, Marymoncka 15
Kazun Nowy, MZ 05152, Poland
Kazun Nowy, MZ 05152, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.
Journal: Molecular biomedicine
Published: July 20, 2025
First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
Journal: Diabetes, obesity & metabolism
Published: September 13, 2023
Discovery and development of CPL207280 as new GPR40/FFA1 agonist.
Journal: European journal of medicinal chemistry
Published: May 18, 2021
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Journal: Molecular pharmacology
Published: February 18, 2021
Elevated Basal Insulin Secretion in Type 2 Diabetes Caused by Reduced Plasma Membrane Cholesterol.
Journal: Molecular endocrinology (Baltimore, Md.)
Published: August 18, 2016
The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.
Journal: Cell metabolism
Published: May 27, 2013
Eukaryotic translation initiation factor 3 subunit e controls intracellular calcium homeostasis by regulation of cav1.2 surface expression.
Journal: PloS one
Published: November 11, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026